{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T15:13:15Z","timestamp":1794496395209,"version":"4.9.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>The objective of this study was to assess the effectiveness and safety of baricitinib (BARI) in interstitial lung disease associated with RA (RA-ILD) in clinical practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>: This was a national multicentre retrospective study of 72 RA-ILD patients treated with BARI. We analysed the following outcomes at baseline and at 3, 6, 12, 18 and 24\u2009months, and at last follow-up: (i) dyspnea (modified Medical Research Council scale), (ii) forced vital capacity (FVC), (iii) diffusing capacity of the lungs for carbon monoxide (DLCO), (iv) chest high-resolution CT (HRCT), (v) arthritis activity (DAS28-ESR), and (vi) CS-sparing effect. Additionally, we analysed the safety data and performed a literature review up to December 2023.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 72 patients (52 women; mean (s.d.) age 68 (10)\u2009years). All patients had received DMARDs. The median [interquartile range (IQR)] ILD duration up to BARI initiation was 25 [13\u201363] months. The most frequent ILD patterns were usual interstitial pneumonia (n\u2009=\u200933; 49%) and non-specific interstitial pneumonia (n\u2009=\u200922; 32%). BARI was used in monotherapy in 43 (60%) patients and combined with conventional synthetic DMARDs in 29 (40%). Mean (s.d.) baseline values of FVC and DLCO (% predicted) were 86 (28) and 69 (20), respectively. After a median [IQR] follow-up of 32 [13\u201365] months, dyspnea, FVC, DLCO and HRCT improved or stabilized in 90%, 88%, 65% and 72%, respectively. The mean DAS28-ESR improved from 4.29 to 2.99, and the median prednisone dose was reduced from 5 to 2.5\u2009mg\/day. Relevant adverse events were uncommon.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>BARI may be a useful and safe alternative in both pulmonary and joint disease in RA-ILD patients, even in refractory cases.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf314","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T16:22:09Z","timestamp":1749572529000},"page":"5471-5480","source":"Crossref","is-referenced-by-count":10,"title":["Baricitinib in rheumatoid arthritis-interstitial lung disease: a literature review and national multicentre study of 72 patients"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-0679-3766","authenticated-orcid":false,"given":"Ana","family":"Serrano-Combarro","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, Immunopathology Group, IDIVAL , Santander,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7119-0786","authenticated-orcid":false,"given":"Bel\u00e9n","family":"Atienza-Mateo","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, Immunopathology Group, IDIVAL , Santander,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6938-5084","authenticated-orcid":false,"given":"Adri\u00e1n","family":"Mart\u00edn-Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, Immunopathology Group, IDIVAL , Santander,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1352-9539","authenticated-orcid":false,"given":"Jes\u00fas","family":"Loarce-Martos","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario Ram\u00f3n y Cajal , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9sar Antonio Eg\u00fces","family":"Dubuc","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario Donostia , San Sebasti\u00e1n,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pastor Mena","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital de Jerez de la Frontera , Jerez de la Frontera,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael B","family":"Melero-Gonzalez","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Complexo Hospitalario Universitario de Ourense , Ourense,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4218-5731","authenticated-orcid":false,"given":"Mar\u00eda","family":"Mart\u00edn L\u00f3pez","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario, 12 de Octubre , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6173-2051","authenticated-orcid":false,"given":"Natalia","family":"Mena V\u00e1zquez","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Regional Universitario de M\u00e1laga , M\u00e1laga,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Carrasco-Cubero","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario de Badajoz , Badajoz,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"P\u00e9rez Garc\u00eda","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital del Mar , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Garc\u00eda","family":"Valle","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Complejo Asistencial Universitario de Palencia , Palencia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gema","family":"Bonilla","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, H. Universitario La Paz , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Mar\u00eda","family":"Blanco Madrigal","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Basurto , Bilbao,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uxue","family":"Astigarraga-Urquia","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario de Navarra , Navarra,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Vegas Revenga","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Galdakao-Usansolo , Bilbao,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena P\u00e9rez","family":"Albadalejo","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario de Ja\u00e9n , Ja\u00e9n,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela","family":"Ortega Castro","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, H.U. Reina Sof\u00eda , C\u00f3rdoba,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deseada","family":"Palma-S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Rafael M\u00e9ndez , Lorca, Murcia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Mar\u00eda","family":"Fern\u00e1ndez Ortiz","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, C.H.U. Badajoz , Badajoz,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia L\u00f3pez","family":"Viejo","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Severo Ochoa , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda L\u00f3pez","family":"Lasanta","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Vall d\u2019Hebron , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Garijo Bufort","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital de Sagunto , Valencia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivette","family":"Casafont Sol\u00e9","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario Germans Trias i Pujol , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Ram\u00f3n","family":"Lamua-Riazuelo","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario del Henares , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio Bra\u00f1a","family":"Abascal","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario Central de Asturias , Oviedo, Asturias,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Ruiz-Esquide","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Clinic de Barcelona , Barcelona,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelin Cecilia","family":"Cervantes P\u00e9rez","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Complexo Hospitalario Universitario de Pontevedra , Pontevedra,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan-Josu\u00e9","family":"Flores Robles","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital San Pedro , Logro\u00f1o,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4837-5237","authenticated-orcid":false,"given":"Mar\u00eda Paz","family":"Mart\u00ednez-Vidal","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital San Juan de Alacant , Alicante,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Moreno Morales","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario Virgen de La Arrixaca , Murcia,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Urruticoechea-Arana","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Son Espases , Palma de Mallorca, Mallorca,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Rosas","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Marina Baixa , Alicante,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9650-1296","authenticated-orcid":false,"given":"Delia","family":"Fern\u00e1ndez-Lozano","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital de M\u00e9rida , Badajoz,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7315-6274","authenticated-orcid":false,"given":"David","family":"Castro Corredor","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital General Universitario de Ciudad Real , Ciudad Real,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-5267","authenticated-orcid":false,"given":"Iv\u00e1n","family":"Ferraz-Amaro","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Complejo Hospitalario Universitario de Canarias , Tenerife,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7748-853X","authenticated-orcid":false,"given":"Santos","family":"Casta\u00f1eda","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario La Princesa, IIS-Princesa , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-2285","authenticated-orcid":false,"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Hospital Universitario Marqu\u00e9s de Valdecilla, Immunopathology Group, IDIVAL , Santander,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Spanish Collaborative Group of JAKi in Interstitial Lung Disease Associated with Rheumatoid Arthritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas Alejandro","family":"Valero-Jaimes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Fern\u00e1ndez","family":"Carballido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Mar\u00eda Rojas","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Arciniega","family":"Larios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan C","family":"Sarmiento-Monroy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"2025100315123583100_keaf314-B1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1080\/1744666X.2021.1905524","article-title":"Rheumatoid arthritis related interstitial lung disease","volume":"17","author":"Manfredi","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"2025100315123583100_keaf314-B2","doi-asserted-by":"crossref","first-page":"220210","DOI":"10.1183\/16000617.0210-2022","article-title":"Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis","volume":"32","author":"Joy","year":"2023","journal-title":"Eur Respir Rev"},{"key":"2025100315123583100_keaf314-B3","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1164\/ajrccm.156.2.9609016","article-title":"Interstitial lung disease in recent onset rheumatoid arthritis","volume":"156","author":"Gabbay","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"2025100315123583100_keaf314-B4","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s10067-010-1492-5","article-title":"Pulmonary involvement in early rheumatoid arthritis patients","volume":"30","author":"Habib","year":"2011","journal-title":"Clin Rheumatol"},{"key":"2025100315123583100_keaf314-B5","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","article-title":"A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality","volume":"76","author":"Hyldgaard","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2025100315123583100_keaf314-B6","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3899\/jrheum.171315","article-title":"Rheumatoid arthritis\u2013interstitial lung disease in the United States: prevalence, incidence, and healthcare costs and mortality","volume":"46","author":"Raimundo","year":"2019","journal-title":"J Rheumatol"},{"key":"2025100315123583100_keaf314-B7","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1093\/rheumatology\/keaa621","article-title":"Abatacept in interstitial lung disease associated with rheumatoid arthritis: national multicenter study of 263 patients","volume":"59","author":"Fern\u00e1ndez-D\u00edaz","year":"2020","journal-title":"Rheumatology"},{"key":"2025100315123583100_keaf314-B8","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3390\/biomedicines10071480","article-title":"Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis\u2013associated interstitial lung disease","volume":"10","author":"Mena-V\u00e1zquez","year":"2022","journal-title":"Biomedicines"},{"key":"2025100315123583100_keaf314-B9","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis\u2013related interstitial lung disease: 10 years\u2019 experience at a single centre","volume":"56","author":"Md Yusof","year":"2017","journal-title":"Rheumatology"},{"key":"2025100315123583100_keaf314-B10","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/rheumatology\/keab317","article-title":"Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis\u2014multicentre study of 263 Caucasian patients","volume":"61","author":"Fern\u00e1ndez-D\u00edaz","year":"2021","journal-title":"Rheumatology"},{"key":"2025100315123583100_keaf314-B11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ejim.2023.08.025","article-title":"Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis","volume":"119","author":"Atienza-Mateo","year":"2024","journal-title":"Eur J Intern Med"},{"key":"2025100315123583100_keaf314-B12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.reumae.2022.03.004","article-title":"SER-SEPAR recommendations for the management of rheumatoid arthritis-related interstitial lung disease. Part 2: treatment","volume":"18","author":"Narv\u00e1ez","year":"2022","journal-title":"Reumatol Cl\u00edn (Engl Ed)"},{"key":"2025100315123583100_keaf314-B13","doi-asserted-by":"crossref","first-page":"e3\u201342","DOI":"10.1093\/rheumatology\/key208","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology"},{"key":"2025100315123583100_keaf314-B14","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK\u2013STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"2025100315123583100_keaf314-B15","doi-asserted-by":"crossref","first-page":"103636","DOI":"10.1016\/j.autrev.2024.103636","article-title":"Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis","volume":"23","author":"Narv\u00e1ez","year":"2024","journal-title":"Autoimmun Rev"},{"key":"2025100315123583100_keaf314-B16","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/biom10071002","article-title":"JAK-inhibitors for the treatment of rheumatoid arthritis: a focus on the present and an outlook on the future","volume":"10","author":"Angelini","year":"2020","journal-title":"Biomolecules"},{"key":"2025100315123583100_keaf314-B17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jbspin.2019.09.005","article-title":"Inhibition of JAK\/STAT signaling in rheumatologic disorders: the expanding spectrum","volume":"87","author":"El Jammal","year":"2020","journal-title":"Joint Bone Spine"},{"key":"2025100315123583100_keaf314-B18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/25785826.2023.2172808","article-title":"JAK inhibitors in rheumatology","volume":"46","author":"Yamaoka","year":"2023","journal-title":"Immunol Med"},{"key":"2025100315123583100_keaf314-B19","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1021\/jm401490p","article-title":"Discovery and development of Janus Kinase (JAK) inhibitors for inflammatory diseases","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"2025100315123583100_keaf314-B20","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s42358-023-00325-z","article-title":"Baricitinib improves pulmonary fibrosis in mice with rheumatoid arthritis-associated interstitial lung disease by inhibiting the Jak2\/Stat3 signaling pathway","volume":"63","author":"Liu","year":"2023","journal-title":"Advances in Rheumatology"},{"key":"2025100315123583100_keaf314-B21","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.3390\/jcm12134527","article-title":"A JAK inhibitor for treatment of rheumatoid arthritis: the baricitinib experience","volume":"12","author":"Taylor","year":"2023","journal-title":"J Clin Med"},{"key":"2025100315123583100_keaf314-B22","doi-asserted-by":"crossref","first-page":"3952","DOI":"10.1093\/rheumatology\/keac068","article-title":"Effectiveness of baricitinib and tofacitinib compared with bDMARDs in RA: results from a cohort study using nationwide Swedish register data","volume":"61","author":"Barbulescu","year":"2022","journal-title":"Rheumatology"},{"key":"2025100315123583100_keaf314-B23","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s40744-023-00597-3","article-title":"Comparative effectiveness, time to discontinuation, and patient-reported outcomes with baricitinib in rheumatoid arthritis: 2-year data from the multinational, prospective observational RA-BE-REAL study in European patients","volume":"10","author":"Alten","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2025100315123583100_keaf314-B24","doi-asserted-by":"crossref","first-page":"e004291","DOI":"10.1136\/rmdopen-2024-004291","article-title":"PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs","volume":"10","author":"van de Laar","year":"2024","journal-title":"RMD Open"},{"key":"2025100315123583100_keaf314-B25","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2025100315123583100_keaf314-B26","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An Official American Thoracic Society\/European Respiratory Society Statement: update of the International Multidisciplinary Classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"2025100315123583100_keaf314-B27","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1378\/chest.93.3.580","article-title":"Evaluation of clinical methods for rating dyspnea","volume":"93","author":"Mahler","year":"1988","journal-title":"Chest"},{"key":"2025100315123583100_keaf314-B28","doi-asserted-by":"crossref","first-page":"1215450","DOI":"10.3389\/fimmu.2023.1215450","article-title":"A prospective observational cohort study of the efficacy of tofacitinib plus iguratimod on rheumatoid arthritis with usual interstitial pneumonia","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"2025100315123583100_keaf314-B29","first-page":"2071","article-title":"Efficacy and safety of tofacitinib in rheumatoid arthritis-associated interstitial lung disease: TReasure real-life data","volume":"40","author":"Kalyoncu","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2025100315123583100_keaf314-B30","doi-asserted-by":"crossref","first-page":"6652845","DOI":"10.1155\/2021\/6652845","article-title":"Tofacitinib for the treatment of severe interstitial lung disease related to rheumatoid arthritis","volume":"2021","author":"Vacchi","year":"2021","journal-title":"Case Rep Med"},{"key":"2025100315123583100_keaf314-B31","first-page":"137","article-title":"Janus kinase inhibitors as a therapeutic option in rheumatoid arthritis and associated interstitial lung disease. Report of four cases","volume":"26","author":"Saldarriaga-Rivera","year":"2019","journal-title":"Rev Colomb Reumatol (Engl Ed)"},{"key":"2025100315123583100_keaf314-B32","doi-asserted-by":"crossref","first-page":"957","DOI":"10.3390\/jcm12030957","article-title":"Evolution of rheumatoid-arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a retrospective exploratory study","volume":"12","author":"Venerito","year":"2023","journal-title":"J Clin Med"},{"key":"2025100315123583100_keaf314-B33","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s10787-022-00936-w","article-title":"A retrospective study of the efficacy of JAK inhibitors or abatacept on rheumatoid arthritis-interstitial lung disease","volume":"30","author":"Tardella","year":"2022","journal-title":"Inflammopharmacology"},{"key":"2025100315123583100_keaf314-B34","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1016\/j.rmed.2012.06.020","article-title":"Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoid arthritis","volume":"106","author":"Wilsher","year":"2012","journal-title":"Respir Med"},{"key":"2025100315123583100_keaf314-B35","doi-asserted-by":"crossref","first-page":"14509","DOI":"10.3390\/ijms241914509","article-title":"Etiology and pathogenesis of rheumatoid arthritis-interstitial lung disease","volume":"24","author":"Kim","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025100315123583100_keaf314-B36","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/acr.25348","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025100315123583100_keaf314-B37","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12026-022-09261-4","article-title":"The Janus kinase inhibitor (baricitinib) suppresses the rheumatoid arthritis active marker gliostatin\/thymidine phosphorylase in human fibroblast-like synoviocytes","volume":"70","author":"Joyo","year":"2022","journal-title":"Immunol Res"},{"key":"2025100315123583100_keaf314-B38","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/rheumatology\/kex426","article-title":"Targeted inhibition of Janus kinases abates interfon gamma-induced invasive behaviour of fibroblast-like synoviocytes","volume":"57","author":"Karonitsch","year":"2018","journal-title":"Rheumatology"},{"key":"2025100315123583100_keaf314-B39","first-page":"442","article-title":"Effects of matrine on JAK-STAT signaling transduction pathways in bleomycin-induced pulmonary fibrosis","volume":"10","author":"Ma","year":"2013","journal-title":"Afr J Tradit Complement Alternat Med"},{"key":"2025100315123583100_keaf314-B40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12931-018-0728-9","article-title":"The JAK2 pathway is activated in idiopathic pulmonary fibrosis","volume":"19","author":"Milara","year":"2018","journal-title":"Respir Res"},{"key":"2025100315123583100_keaf314-B41","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/14740338.2021.1973428","article-title":"Efficacy and safety of biological drugs in interstitial lung disease associated with connective tissue diseases","volume":"21","author":"Vicente-Rabaneda","year":"2022","journal-title":"Expert Opin Drug Saf"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf314\/63464950\/keaf314.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/10\/5471\/63464950\/keaf314.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/10\/5471\/63464950\/keaf314.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:12:47Z","timestamp":1759518767000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/10\/5471\/8160025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,6,10]]},"published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf314","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,6,10]]}}}